Gastric Cancer – Pipeline Review, H2 2020

Research By Markets adds Market Research Report - Gastric Cancer – Pipeline Review, H2 2020

For detailed information: https://www.researchbymarkets.com/report/gastric-cancer-pipeline-review-h2-2020-665850.html

Gastric Cancer – Pipeline Review, H2 2020

Summary

Gastric Cancer – Pipeline Review, H2 2020, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Gastric Cancer – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 17, 134, 194, 1, 18, 159, 35 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 12, 9, 1, 10 and 4 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
3SBio Inc
AbbVie Inc
AbClon Inc
Abion Inc
ABL Bio Inc
Abpro Corp
Acepodia Biotech Inc
Acrotech Biopharma LLC
AD Pharmaceuticals Co Ltd
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Advenchen Laboratories LLC
Affimed GmbH
AffyImmune Therapeutics Inc
Arog Pharmaceuticals Inc
Biomunex Pharmaceuticals
BioNTech SE
Biosion Inc
Biotecnol Ltd
BJ Bioscience Inc
Bliss Biopharmaceutical (Hangzhou) Co Ltd
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
Byondis BV
CalyGene Biotechnology Inc
Camel-IDS NV
Cancer Prevention Pharmaceuticals Inc
Cannabics Pharmaceuticals Inc
CARsgen Therapeutics Ltd
CAS-Lamvac Biotech Co Ltd
Catalent Inc
Celldex Therapeutics Inc
CureLab Oncology Inc
CureMeta LLC
Cynvec LLC
Cytocom Inc
Cytodyn Inc
CytoMed Therapeutics Pte Ltd
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Delta-Fly Pharma Inc
DiNonA Inc
DM Bio Ltd
Dr. Reddy’s Laboratories Ltd
Dragonfly Therapeutics Inc
Eddingpharm Inc
eFFECTOR Therapeutics Inc
Genexine Inc
Genmab AS
Gilead Sciences Inc
GlaxoSmithKline Plc
GLG Pharma SA
GlycoNex Inc
Glycotope GmbH
Good T Cells Inc
Gossamer Bio Inc
Green Cross LabCell Corp
Grid Therapeutics LLC
Guangdong Zhongsheng Pharmaceutical Co Ltd
HaimBio Ltd
Hangzhou DAC Biotech Co Ltd
Hanmi Pharmaceuticals Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Jiuzhitang Co Ltd
Johnson & Johnson
Jounce Therapeutics Inc
JW Pharmaceutical Corp
Karyopharm Therapeutics Inc
KLUS Pharma Inc
Komipharm International Co Ltd
Konruns Pharmaceutical Co Ltd
Kringle Pharma Inc
Kupffer Biotherapeutics Inc
Kymab Ltd
Kyowa Kirin Co Ltd
LATITUDE Pharmaceuticals Inc
Leap Therapeutics Inc
Legend Biotech Corp
Ocellaris Pharma Inc
Ona Therapeutics SL
OncoImmune Inc
Oncolys BioPharma Inc
OncoSynergy Inc
OncoTherapy Science Inc
OncXerna Therapeutics Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Opsona Therapeutics Ltd
Orano Med LLC
Origincell Technology Group Co Ltd
Oxford BioTherapeutics Ltd
Patrys Ltd
Peptron Inc
PersonGen Biomedicine Suzhou Co Ltd
Pfizer Inc
Phanes Therapeutics Inc
Pharma Mar SA
Pharmapraxis
Philogen SpA
Phosplatin Therapeutics LLC
Pieris Pharmaceuticals Inc
Plus Therapeutics Inc
PNB Vesper Life Science Pvt Ltd
Prescient Therapeutics Ltd
Prestige BioPharma Pte Ltd
ProLynx LLC
Protheragen Inc
Puma Biotechnology Inc
QED Therapeutics Inc
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Quadriga BioSciences Inc
QureBio Ltd
Rakuten Medical Inc
RAPT Therapeutics Inc
RaQualia Pharma Inc
Redx Pharma Plc
Relay Therapeutics Inc
RemeGen Ltd
Rhizen Pharmaceuticals SA
RUS Pharmtech
Samumed LLC
Samyang Holdings Corp
Sanofi
Scancell Holdings Plc
Seagen Inc
SELLAS Life Sciences Group Inc
Seven and Eight Biopharmaceuticals Corp
Shandong Golden Brick Biotechnology Co Ltd
Shanghai Biomed-Union Biotechnology Co Ltd
Shanghai Bioray Laboratory Inc
Shanghai GeneChem Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Bioscience Co Ltd
Shanghai Keqi Pharmaceutical Technology Co Ltd
Shanghai Miracogen Inc
Shanghai PerHum Therapeutics Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shaperon Inc
Shenyang Dongxing Pharmaceutical Co Ltd
Shenzhen BinDeBio Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Fapon Biopharma Inc
Shenzhen Hornetcorn Bio-technology Company Ltd
Shenzhen NeoCura Biotechnology Corp
Shijiazhuang No. 4 Pharmaceutical Co Ltd
Shijiazhuang Sagacity New Drug Development Co Ltd
Shionogi & Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Silicon Therapeutics LLC
Sillajen Biotherapeutics
Sino Biopharmaceutical Ltd
SN BioScience
Sorrento Therapeutics Inc
Sotio AS
Sparx Therapeutics Inc
Spring Bank Pharmaceuticals Inc
Stcube Inc
Stemirna Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Sunstem Biotechnology Co Ltd
Suntec Medical (Taiwan) Inc
Suzhou Sinovent Pharmaceuticals Co Ltd
Suzhou Zanrong Pharmaceutical Technology Co Ltd
SynCore Biotechnology Co Ltd
Systimmune Inc
T-Cure Bioscience Inc
TAE Life Sciences LLC
Taiho Oncology Inc
Taiho Pharmaceutical Co Ltd
Takis Srl
Tarveda Therapeutics Inc
Tasly Pharmaceutical Group Co Ltd
Tempest Therapeutics Inc
Tessa Therapeutics Ltd
Themis Bioscience GmbH
Tonix Pharmaceuticals Holding Corp
Toray Industries Inc
TOT Biopharm Co Ltd
Transcenta Holding Ltd
Transcode√ā¬†Therapeutics Inc
Treos Bio Ltd
Trio Medicines Ltd
Triumvira Immunologics Inc
Turning Point Therapeutics Inc
Turnstone Biologics Inc
Tvardi Therapeutics Inc
Tyg Oncology Ltd
Ube Industries Ltd
United BioPharma Inc
Vaxon Biotech
Vedanta Biosciences Inc
Venus Remedies Ltd
Viracta Therapeutics Inc
Viral Gene Inc
Viralytics Pty Ltd
VM Discovery Inc
WellMarker Bio Co Ltd
Wellmarker Bio Co Ltd
Wuhan YZY Biopharma Co Ltd
Xcovery Holding Co LLC
Xencor Inc
Xiangxue Life Sciences
XuanZhu Pharma Co Ltd
Zai Lab Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Jianfeng Group Company Ltd
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
Zymeworks Inc


For queries regarding this report: https://www.researchbymarkets.com/sample-request/665850

Contact Us:
ResearchByMarkets.com
Sales Desk
enquiry@researchbymarkets.com
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via ritesh@researchbymarkets.com. *Market Research News is a part of Research By Markets.